1. Insulin resistance influences central opioid activity in polycystic ovary syndrome.
- Author
-
Berent-Spillson A, Love T, Pop-Busui R, Sowers M, Persad CC, Pennington KP, Eyvazaddeh AD, Padmanabhan V, Zubieta JK, and Smith YR
- Subjects
- Adult, Binding Sites, Brain drug effects, Carbon Radioisotopes, Case-Control Studies, Female, Fentanyl analogs & derivatives, Fentanyl metabolism, Glucose Tolerance Test, Humans, Hypoglycemic Agents therapeutic use, Magnetic Resonance Imaging, Metformin therapeutic use, Michigan, Pilot Projects, Polycystic Ovary Syndrome drug therapy, Polycystic Ovary Syndrome physiopathology, Positron-Emission Tomography, Receptors, Opioid, mu drug effects, Time Factors, Treatment Outcome, Young Adult, Brain metabolism, Insulin Resistance, Polycystic Ovary Syndrome metabolism, Receptors, Opioid, mu metabolism, beta-Endorphin metabolism
- Abstract
This pilot study describes a relationship between insulin resistance and μ-opioid neurotransmission in limbic appetite and mood-regulating regions in women with polycystic ovary syndrome (PCOS), suggesting that insulin-opioid interactions may contribute to behavioral and reproductive pathologies of PCOS. We found that [1] patients with PCOS who are insulin-resistant (n = 7) had greater limbic μ-opioid receptor availability (nondisplaceable binding potential) than controls (n = 5); [2] receptor availability was correlated with severity of insulin resistance; and [3] receptor availability normalized after insulin-regulating treatment., (Copyright © 2011 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved.)
- Published
- 2011
- Full Text
- View/download PDF